Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 2,123 | $118.47 | $251,514.78 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 8 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,427 F8 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,123 shares in multiple trades at prices ranging from $117.91 to $118.90. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 999 | $117.01 | $116,894.09 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 7 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,550 F7 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 999 shares in multiple trades at prices ranging from $116.85 to $117.82. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 1,395 | $116.06 | $161,906.21 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 6 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,549 F6 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 1,395 shares in multiple trades at prices ranging from $115.79 to $116.45. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 3,702 | $115.21 | $426,512.23 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 5 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,944 F5 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 3,702 shares in multiple trades at prices ranging from $114.79 to $115.78. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 4,568 | $114.35 | $522,361.76 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 4 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,646 F4 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 4,568 shares in multiple trades at prices ranging from $113.76 to $114.75. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 2,000 | $112.86 | $225,726.40 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,214 F3 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 2,000 shares in multiple trades at prices ranging from $112.29 to $113.26. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
SaleOrdinary Shares | 8,369 | $111.23 | $930,915.67 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,214 F2 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 8,369 shares in multiple trades at prices ranging from $111.00 to $111.97. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:18 UTC |
Danziger AsafDirector · Chief Executive Officer
|
Exercise / conversionOrdinary Shares | 25,000 | $11.46 | $286,500.00 |
DisclosureSEC source: 0001645113-23-000007 · wf-form4_167330630889022.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Danziger. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:33 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,000 | $7.15 Strike: $7.15 | $14,300.00 |
DisclosureSEC source: 0001645113-22-000096 · wf-form4_167027597587120.xml · derivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,752 Underlying: Ordinary Shares · 2,000 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:33 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOrdinary Shares | 2,000 | $7.15 | $14,300.00 |
DisclosureSEC source: 0001645113-22-000096 · wf-form4_167027597587120.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:42 UTC |
Leonard Frank XPresident, CNS Cancers US
|
GrantOptions to Buy Ordinary Shares · Derivative | 11,609 | $73.20 Strike: $73.20 | $849,778.80 |
DisclosureSEC source: 0001645113-22-000093 · wf-form4_166750812638914.xml · derivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,609 Underlying: Ordinary Shares · 11,609 shares Expires 2032-10-31 F2 · shares: Options to buy 11,609 ordinary shares will vest and become exercisable in equal installments on each of November 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 01, 2022 Filed Nov 3, 2022 20:42 UTC |
Leonard Frank XPresident, CNS Cancers US
|
GrantOrdinary Shares | 6,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000093 · wf-form4_166750812638914.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,456 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of November 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:35 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 6,754 | $76.01 | $513,371.54 |
DisclosureSEC source: 0001645113-22-000086 · wf-form4_166603866486448.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,626 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:16 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 6,754 | $84.37 | $569,834.98 |
DisclosureSEC source: 0001645113-22-000085 · wf-form4_166517377413417.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,380 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:20 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 6,754 | $77.35 | $522,421.90 |
DisclosureSEC source: 0001645113-22-000084 · wf-form4_166456919628442.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,134 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 20:19 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 6,754 | $77.00 | $520,058.00 |
DisclosureSEC source: 0001645113-22-000083 · wf-form4_166422355748808.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,888 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC |
Leonard Frank XChief Development Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,517 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · derivative · entry 4 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,517 Underlying: Ordinary Shares · 5,517 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 5,517 | $90.00 | $496,530.00 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,642 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 6,754 | $87.31 | $589,691.74 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,159 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:10 UTC |
Leonard Frank XChief Development Officer
|
Exercise / conversionOrdinary Shares | 5,517 | $7.15 | $39,446.55 |
DisclosureSEC source: 0001645113-22-000082 · wf-form4_166361822021489.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:32 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,863 | $88.00 | $163,944.00 |
DisclosureSEC source: 0001645113-22-000080 · wf-form4_166301475766544.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,150 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 08, 2022 Filed Sep 13, 2022 20:15 UTC Amendment |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 6,754 | $81.48 | $550,315.92 |
DisclosureSEC source: 0001645113-22-000081 · wf-form4a_166310011170112.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,396 F1 · security: Amending original Form 4 filed on September 12, 2022 to add additional transaction inadvertently omitted. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 20:27 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,384 | $78.57 | $108,740.88 |
DisclosureSEC source: 0001645113-22-000079 · wf-form4_166258244880634.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,013 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 17:16 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 718 | $79.04 | $56,748.57 |
DisclosureSEC source: 0001645113-22-000078 · wf-form4_166249898623741.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,486 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 21:15 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 885 | $79.04 | $69,947.75 |
DisclosureSEC source: 0001645113-22-000077 · wf-form4_166249891435026.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,376 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 21:14 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 296 | $79.04 | $23,394.95 |
DisclosureSEC source: 0001645113-22-000076 · wf-form4_166249884466171.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,024 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 21:12 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 269 | $79.04 | $21,260.95 |
DisclosureSEC source: 0001645113-22-000075 · wf-form4_166249873695422.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,230 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 584 | $79.04 | $46,157.61 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 13 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,397 F14 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 48 | $78.96 | $3,789.89 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 12 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,981 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F13 · price: On September 1, 2022, Mr. Leonard sold 48 shares in multiple trades at prices ranging from $78.70 to $79.28. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 438 | $78.14 | $34,225.32 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 11 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,029 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F12 · price: On September 1, 2022, Mr. Leonard sold 438 shares in multiple trades at prices ranging from $77.59 to $78.58. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 360 | $77.06 | $27,742.32 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 10 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,467 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F11 · price: On September 1, 2022, Mr. Leonard sold 360 shares in multiple trades at prices ranging from $76.57 to $77.48. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 240 | $75.88 | $18,210.00 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 9 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,827 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F10 · price: On September 1, 2022, Mr. Leonard sold 240 shares in multiple trades at prices ranging from $75.42 to $76.41. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,088 | $78.68 | $85,601.66 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 8 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,067 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F9 · price: On September 1, 2022, Mr. Leonard sold 1,088 shares in multiple trades at prices ranging from $78.46 to $79.28. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 2,720 | $77.92 | $211,934.24 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 7 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,155 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F8 · price: On September 1, 2022, Mr. Leonard sold 2,720 shares in multiple trades at prices ranging from $77.42 to $78.39. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,750 | $76.96 | $134,676.50 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 6 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,875 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F7 · price: On September 1, 2022, Mr. Leonard sold 1,750 shares in multiple trades at prices ranging from $76.41 to $77.33. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,200 | $75.93 | $91,113.60 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 5 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,625 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F6 · price: On September 1, 2022, Mr. Leonard sold 1,200 shares in multiple trades at prices ranging from $75.41 to $76.31. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 452 | $78.66 | $35,555.68 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 4 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,825 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · price: On September 1, 2022, Mr. Leonard sold 452 shares in multiple trades at prices ranging from $78.57 to $78.74. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 2,955 | $78.09 | $230,741.18 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,277 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F4 · price: On September 1, 2022, Mr. Leonard sold 2,955 shares in multiple trades at prices ranging from $77.57 to $78.56. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,914 | $77.00 | $147,381.83 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,232 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F3 · price: On September 1, 2022, Mr. Leonard sold 1,914 shares in multiple trades at prices ranging from $76.54 to $77.42. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:19 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 1,047 | $75.94 | $79,503.95 |
DisclosureSEC source: 0001645113-22-000074 · wf-form4_166249553777247.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,146 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F2 · price: On September 1, 2022, Mr. Leonard sold 1,047 shares in multiple trades at prices ranging from $75.42 to $76.37. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:32 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 5,396 | $74.00 | $399,304.00 |
DisclosureSEC source: 0001645113-22-000073 · wf-form4_165964508670843.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,672 Read SEC document |
| August 03, 2022 Filed Aug 4, 2022 20:32 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 563 | $71.09 | $40,023.67 |
DisclosureSEC source: 0001645113-22-000073 · wf-form4_165964508670843.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,068 F1 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:45 UTC |
Cordova AshleyChief Financial Officer
|
GrantOrdinary Shares | 7,122 | $70.20 | $499,964.40 |
DisclosureSEC source: 0001645113-22-000072 · wf-form4_165955948883661.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,261 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of August 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:44 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
SaleOrdinary Shares | 837 | $69.66 | $58,304.58 |
DisclosureSEC source: 0001645113-22-000071 · wf-form4_165955946744367.xml · nonDerivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,176 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:44 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 437 | $69.66 | $30,440.98 |
DisclosureSEC source: 0001645113-22-000070 · wf-form4_165955944560794.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,631 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:44 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 414 | $69.66 | $28,838.83 |
DisclosureSEC source: 0001645113-22-000069 · wf-form4_165955941387882.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,193 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:44 UTC |
Burke William PatrickChief Human Resources Officer
|
GrantOrdinary Shares | 213 | $59.08 | $12,582.98 |
DisclosureSEC source: 0001645113-22-000058 · wf-form4_165723028456783.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,204 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 17:51 UTC |
Weinberg UriChief Science Officer
|
GrantOrdinary Shares | 281 | $59.08 | $16,600.08 |
DisclosureSEC source: 0001645113-22-000066 · wf-form4_165723064834354.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,483 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:48 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 218 | $59.08 | $12,878.35 |
DisclosureSEC source: 0001645113-22-000063 · wf-form4_165723051770430.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,320 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:50 UTC |
Ben Arye BarakGeneral Counsel
|
GrantOrdinary Shares | 144 | $59.08 | $8,506.80 |
DisclosureSEC source: 0001645113-22-000065 · wf-form4_165723060256540.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,002 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.